Cyclosporine therapeutic monitoring with CMAX in kidney transplant recipients: racial considerations

El‐Agroudy, Amgad E.; Ismail, Amani; Nassar, M. Sh.; Ghoneim, Mohamed A.

doi:10.1007/s10157-008-0111-0

Cited by 1 publication

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Due to its interactions with immunosuppressive agents in solid organ transplant recipients, rifampicin-based ATT is often seen to be associated with increased risk of rejections, graft dysfunction, and allograft failure. [18][19][20] Rifabutin has been used in solid organ transplantation as it is a less-potent inducer of the cytochrome P-450 system. Nevertheless, such cases may need an increase in the tacrolimus dose to 1.5 times the baseline dose.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Kidney transplantation in patients on anti‐tubercular therapy: A single centre observational study

Prasad,

Bagai,

Prasad

et al. 2024

Transplant Infectious Dis

View full text Add to dashboard Cite

BackgroundTuberculosis (TB) is a common infection in chronic kidney disease. The prolonged therapy of TB can delay kidney transplantation in patients on antitubercular therapy (ATT).MethodsThis was a retrospective single‐center study to analyze the safety of kidney transplantation and its outcomes in patients undergoing transplantation while on the continuation phase of ATT.ResultsBetween 2013 and 2022, 30 patients underwent kidney transplantation while on ATT. Median age was 38 years and 70% were males. Majority of the patients (86.7%) had extrapulmonary tuberculosis, most common site of involvement being tubercular lymphadenitis. 14/30 patients had microbiological/histopathological diagnosis of TB and the rest were diagnosed by ancillary tests. Patients were treated with 4 drug ATT (isoniazid, rifampicin, pyrazinamide, ethambutol) before transplantation for aminimum of 2 months. Post‐transplantation fluoroquinolone‐based non‐rifamycin ATT was used (median duration 11 months). All patients completed therapy. At 2 years, there was 100% patient survival and 96.7% graft survival. Median eGFR at 6, 12, and 24 months post‐transplantation was 71.9, 64.7, and 67 mL/min/1.73m2, respectively. The percentage of patients suffering a biopsy proven acute rejection at 6, 12, and 24 months was 3.3%, 6.7%, and 6.7%.ConclusionKidney transplantation can be done in patients with TB who have a satisfactory response to the intensive phase of the ATT. The decision for transplantation while on the continuation phase of ATT should be individualized. In our experience, there is excellent patient and graft survival in these patients with a low risk of failure of ATT or relapse of TB. image

show abstract

Section: Discussionmentioning

confidence: 99%

“…The median duration of ATT post-transplantation was 11 months (range 3-24 months). The median total duration of ATT was 14(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27) months. The median duration of ATT for patients with pulmonary TB was 19.5 months (12-27m) and for extrapulmonary TB was 14 months (12-23 months).…”

mentioning

confidence: 99%